No Data
Investors in Genscript Biotech (HKG:1548) From Three Years Ago Are Still Down 51%, Even After 7.1% Gain This Past Week
Zhitong Hong Kong Stock Early Knowledge | The Ministry of Industry and Information Technology released the key points of automotive standardization work for 2025, ahead of schedule conducting research on the standardization needs of new business formats s
The Ministry of Industry and Information Technology released the key points for vehicle standardization work in 2025. It proposed to proactively layout standards research in cutting-edge fields. Analyzing and assessing the development trends of cutting-edge technologies and potential application scenarios, identifying and evaluating the future direction of vehicle standardization development, promoting the formulation and release of standard sub-systems for automotive AI, Solid State Battery, electric vehicle battery swapping, and initiating the construction of standard systems for new fields such as data governance and application, while conducting advanced research on standardization needs for new business formats like flying cars.
GENSCRIPT BIO (01548.HK) plans to purchase a total of 0.3 billion Class A preferred shares of Probio Cayman for approximately 1.7 billion HKD.
On April 28, GENSCRIPT BIO (01548.HK) announced that on April 28, 2025, the transferor, the transferee (the company's wholly-owned subsidiary), and the company entered into a share transfer agreement, under which the transferee agrees to purchase from the transferor and the transferor agrees to sell to the transferee a total of 0.3 billion shares of Probio Cayman Class A preferred shares, with an aggregate consideration of approximately 0.225 billion USD (equivalent to approximately 1.7 billion HKD) at the time of delivery. As of the date of this announcement, without considering the future issuance of shares under the employee stock ownership plan, the company directly and through its wholly-owned subsidiary...
Express News | Genscript Biotech - Unit to Buy 300.0 Mln Series a Preferred Shares of Probio Cayman in Aggregate for US$225.1 Mln
Express News | Bestzyme's Mellia™ Brazzein Receives FDA "No Questions" Letter, Bringing Creative Sugar Reduction Solution to Global Market
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Genscript Biotech Corporation's (HKG:1548) P/S Is Still On The Mark Following 29% Share Price Bounce
